The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in...

Ghandour Cosmetics Ltd., a leading name in Ghana’s beauty and personal care industry for 28 years, is excited to announce Ghanaian actress and TV...

The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.

The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.

With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.

Highlights: EBGLYSS targets IL-13 to reduce eczema inflammation and itching FDA approval was based on successful